Principia Biopharma CEO Martin Babler's 2019 pay jumps 118% to $5.1M
Principia Biopharma reports 2019 executive compensation
By ExecPay News
Published: April 24, 2020
Principia Biopharma reported fiscal year 2019 executive compensation information on April 24, 2020.
In 2019, three executives at Principia Biopharma received on average a compensation package of $3.2M, a 30% increase compared to previous year.
Average pay of disclosed executives at Principia Biopharma
Martin Babler, Chief Executive Officer, received $5.1M in total, which increased by 118% compared to 2018. 81% of Babler's compensation, or $4.1M, was in option awards. Babler also received $417K in non-equity incentive plan, $556K in salary, as well as $1K in other compensation.
David M. Goldstein, Chief Scientific Officer, received a compensation package of $2.2M. 71% of the compensation package, or $1.6M, was in option awards.
Dolca Thomas, Chief Medical Officer, earned $2.2M in 2019, a 39% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 24, 2020.